Logo image of MXCT

MAXCYTE INC (MXCT) Stock Fundamental Analysis

NASDAQ:MXCT - Nasdaq - US57777K1060 - Common Stock - Currency: USD

3.85  -0.11 (-2.78%)

After market: 3.85 0 (0%)

Fundamental Rating

4

MXCT gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. No worries on liquidiy or solvency for MXCT as it has an excellent financial health rating, but there are worries on the profitability. MXCT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

MXCT had negative earnings in the past year.
In the past year MXCT has reported a negative cash flow from operations.
In the past 5 years MXCT always reported negative net income.
In the past 5 years MXCT always reported negative operating cash flow.
MXCT Yearly Net Income VS EBIT VS OCF VS FCFMXCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

MXCT has a Return On Assets (-14.37%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -16.75%, MXCT is in line with its industry, outperforming 59.65% of the companies in the same industry.
Industry RankSector Rank
ROA -14.37%
ROE -16.75%
ROIC N/A
ROA(3y)-9.69%
ROA(5y)-18.98%
ROE(3y)-10.96%
ROE(5y)-32.67%
ROIC(3y)N/A
ROIC(5y)N/A
MXCT Yearly ROA, ROE, ROICMXCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 100

1.3 Margins

The Gross Margin of MXCT (85.98%) is better than 100.00% of its industry peers.
In the last couple of years the Gross Margin of MXCT has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for MXCT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.34%
GM growth 5Y-0.1%
MXCT Yearly Profit, Operating, Gross MarginsMXCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100

More info and screens

8

2. Health

2.1 Basic Checks

MXCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MXCT has been increased compared to 1 year ago.
The number of shares outstanding for MXCT has been increased compared to 5 years ago.
There is no outstanding debt for MXCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MXCT Yearly Shares OutstandingMXCT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
MXCT Yearly Total Debt VS Total AssetsMXCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

MXCT has an Altman-Z score of 6.27. This indicates that MXCT is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of MXCT (6.27) is better than 87.72% of its industry peers.
MXCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.27
ROIC/WACCN/A
WACC11.32%
MXCT Yearly LT Debt VS Equity VS FCFMXCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M 200M 250M

2.3 Liquidity

A Current Ratio of 9.81 indicates that MXCT has no problem at all paying its short term obligations.
The Current ratio of MXCT (9.81) is better than 89.47% of its industry peers.
A Quick Ratio of 9.22 indicates that MXCT has no problem at all paying its short term obligations.
MXCT has a better Quick ratio (9.22) than 91.23% of its industry peers.
Industry RankSector Rank
Current Ratio 9.81
Quick Ratio 9.22
MXCT Yearly Current Assets VS Current LiabilitesMXCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

6

3. Growth

3.1 Past

MXCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.11%, which is quite good.
Looking at the last year, MXCT shows a quite strong growth in Revenue. The Revenue has grown by 19.87% in the last year.
The Revenue has been growing by 19.89% on average over the past years. This is quite good.
EPS 1Y (TTM)8.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)19.87%
Revenue growth 3Y16.41%
Revenue growth 5Y19.89%
Sales Q2Q%1.99%

3.2 Future

MXCT is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.16% yearly.
Based on estimates for the next years, MXCT will show a very strong growth in Revenue. The Revenue will grow by 26.51% on average per year.
EPS Next Y-13.03%
EPS Next 2Y-3.91%
EPS Next 3Y1.16%
EPS Next 5YN/A
Revenue Next Year-4.83%
Revenue Next 2Y6.97%
Revenue Next 3Y12.83%
Revenue Next 5Y26.51%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MXCT Yearly Revenue VS EstimatesMXCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M
MXCT Yearly EPS VS EstimatesMXCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MXCT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MXCT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MXCT Price Earnings VS Forward Price EarningsMXCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MXCT Per share dataMXCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.91%
EPS Next 3Y1.16%

More info and screens

0

5. Dividend

5.1 Amount

MXCT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MAXCYTE INC

NASDAQ:MXCT (2/21/2025, 8:00:01 PM)

After market: 3.85 0 (0%)

3.85

-0.11 (-2.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)03-11 2025-03-11/amc
Inst Owners69.8%
Inst Owner Change5.77%
Ins Owners0.82%
Ins Owner Change0.4%
Market Cap406.98M
Analysts88.33
Price Target9.44 (145.19%)
Short Float %2.69%
Short Ratio4.95
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.45%
Min EPS beat(2)12.56%
Max EPS beat(2)30.34%
EPS beat(4)4
Avg EPS beat(4)26.74%
Min EPS beat(4)12.56%
Max EPS beat(4)32.13%
EPS beat(8)6
Avg EPS beat(8)16.6%
EPS beat(12)10
Avg EPS beat(12)18.15%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)18.81%
Min Revenue beat(2)8.53%
Max Revenue beat(2)29.09%
Revenue beat(4)4
Avg Revenue beat(4)25.98%
Min Revenue beat(4)8.53%
Max Revenue beat(4)49.02%
Revenue beat(8)5
Avg Revenue beat(8)8.51%
Revenue beat(12)9
Avg Revenue beat(12)9.15%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)1.35%
EPS NQ rev (3m)-2.82%
EPS NY rev (1m)0.41%
EPS NY rev (3m)1.2%
Revenue NQ rev (1m)3.82%
Revenue NQ rev (3m)3.82%
Revenue NY rev (1m)0.75%
Revenue NY rev (3m)1.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.93
P/FCF N/A
P/OCF N/A
P/B 1.91
P/tB 1.91
EV/EBITDA N/A
EPS(TTM)-0.34
EYN/A
EPS(NY)-0.4
Fwd EYN/A
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.18
OCFYN/A
SpS0.43
BVpS2.02
TBVpS2.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.37%
ROE -16.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 85.98%
FCFM N/A
ROA(3y)-9.69%
ROA(5y)-18.98%
ROE(3y)-10.96%
ROE(5y)-32.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.34%
GM growth 5Y-0.1%
F-Score3
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 55.38%
Cap/Sales 5.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.81
Quick Ratio 9.22
Altman-Z 6.27
F-Score3
WACC11.32%
ROIC/WACCN/A
Cap/Depr(3y)347.62%
Cap/Depr(5y)289.64%
Cap/Sales(3y)20.67%
Cap/Sales(5y)15.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-13.03%
EPS Next 2Y-3.91%
EPS Next 3Y1.16%
EPS Next 5YN/A
Revenue 1Y (TTM)19.87%
Revenue growth 3Y16.41%
Revenue growth 5Y19.89%
Sales Q2Q%1.99%
Revenue Next Year-4.83%
Revenue Next 2Y6.97%
Revenue Next 3Y12.83%
Revenue Next 5Y26.51%
EBIT growth 1Y1.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year29.41%
EBIT Next 3Y15.6%
EBIT Next 5YN/A
FCF growth 1Y21.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-94.67%
OCF growth 3YN/A
OCF growth 5YN/A